New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1/S-phase transition

Leukemia

Volumn 22, Issue 8, 2008, Pages 1557-1566

  Chaligne R ^a,b,c   Tonetti, C ^d   Besancenot, R ^a,b,c   Roy, L ^a,b,c,e   Marty, C ^a,b,c   Mossuz, P ^f   Kiladjian, J J ^g   Socie G ^h   Bordessoule, D ⁱ   Le Bousse Kerdiles M C ^a   Vainchenker, W ^a,b,c   Giraudier, S ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e UNIVERSITÉ DE POITIERS   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN P13K; RAS PROTEIN; STAT PROTEIN; THROMBOPOIETIN RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL LINE; CELL MUTANT; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; EXON; GENE ACTIVATION; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; MYELOID METAPLASIA; NONHUMAN; PHASE TRANSITION; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 49449094277     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.137     Document Type: Article

References (32)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
2. Spivak JL. The chronic myeloproliferative disorders: Clonality and clinical heterogeneity.Semin Hematol 2004; 41 (2 Suppl 3): 1-5.
3. Delhommeau F, Dupont S, Tonetti C, Masse A, Godin I, Le Couedic JP et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007; 109: 71-77.
4. Chaligne R, James C, Tonetti C, Besancenot R, Le Couedic JP, Fava F et al. Evidence for MPIL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007; 110: 3735-3743.
5. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelooenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993; 90: 3755-3759.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al Activating mutation in the tyrosine kinase JAK2 in polvcythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
8. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
9. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
10. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of he tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005; 365: 1054-1061.
11. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
12. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplosia. PLoS Med 2006; 3: E270.
13. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 2006; 107: 1864-1871.
14. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H. A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia 2002; 16: 1500-1506.
15. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A et al Familial essential thrombocythemia associated with a dominant-positive activating mutaton of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103: 4198-4200.
16. Goncalves F, Lacout C, Villeval JL, Wendling F, Vainchenker W, Dumenil D. Thrombopoietin does not induce lineage-restricted commitment of Mpl-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation. Blood 1997; 89: 3544-3553.
17. Takahashi A, Kono K, Amemiya H, Iizuka H, Fujii H, Matsumoto Y. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res 2001; 7: 74-80.
18. Helson L, Das SK, Hajdu SI. Human neuroblastoma in nude mice. Cancer Res 1975; 35: 2594-2599.
19. Onishi M, Mui AL, Morikawa Y, Cho L, Kinoshita S, Nolan GP et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood 1996; 88: 1399-1406.
20. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-MpI induce constitutive receptor activity and tumorigenicity. EMBO J 1995; 14: 5569-5578.
21. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63: 1137-1147.
22. Palacios R, Steinmetz M. II-3-dependent mouse clones that express B-220 surlace antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985; 41: 727-734.
23. Drachman JG, Griffin JD, Kaushansky K. The c-MpI ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-MpI. J Biol Chem 1995; 270: 4979-4982.
24. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR et al. Photochemical preparation of a pyridone containing tetracycle: A Jak proteinkinase inhibitor. Bioorg Med Chem Lett 2002; 12: 1219-1223.
25. Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L. PI 3-kinase activation in BCR/abl -transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 1996; 88: 1542-1550.
26. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p240 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 1993; 21: 1460-1466.
27. Jin L, Siritanaratkul N, Emery DW, Richard RE, Kaushansky K, Papayannopoulou T et al. Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci USA 1998; 95: 8093-8097.
28. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997; 15: 2333-2342.
29. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000; 95: 2076-2083.
30. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M et al. TEL-JAK2 fusion protein with constitutive kinak activity in human leukemia. Science 1997; 278: 1309-1312.
31. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 2006; 281: 18177-18183.
32. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007; 35: 1641-1646.